Chromatin topology defines estradiol-primed progesterone receptor and PAX2 binding in endometrial cancer cells
Abstract
Estrogen (E2) and Progesterone (Pg), via their specific receptors (ERalpha and PR), are major determinants in the development and progression of endometrial carcinomas, However, their precise mechanism of action and the role of other transcription factors involved are not entirely clear. Using Ishikawa endometrial cancer cells, we report that E2 treatment exposes a set of progestin-dependent PR binding sites which include both E2 and progestin target genes. ChIP-seq results from hormone-treated cells revealed a non-random distribution of PAX2 binding in the vicinity of these estrogen-promoted PR sites. Altered expression of hormone regulated genes in PAX2 knockdown cells suggests a role for PAX2 in fine-tuning ERalpha and PR interplay in transcriptional regulation. Analysis of long-range interactions by Hi-C coupled with ATAC-seq data showed that these regions, that we call 'progestin control regions' (PgCRs), exhibited an open chromatin state even before hormone exposure and were non-randomly associated with regulated genes. Nearly 20% of genes potentially influenced by PgCRs were found to be altered during progression of endometrial cancer. Our findings suggest that endometrial response to progestins in differentiated endometrial tumor cells results in part from binding of PR together with PAX2 to accessible chromatin regions. What maintains these regions open remains to be studied.
Data availability
All raw and processed sequencing data generated in this study have been submitted to the NCBI Gene Expression Omnibus under accession number GSE139398 (reviewer access: ergbqgaebbmjrmt).Source data file has been provided for Figure 6.T47D ChIPseq data is available under GEO accession number GSE41466 (Ballare et al, 2013) and Hi-C data in GEO accession GSE53463 (Le-Dily et al, 2014). RNAseq datasets from proliferative (GSM3890623, GSM3890624, GSM3890625 and GSM3890626) and mid-secretory (GSM3890627, GSM3890628, GSM3890629, GSM3890630 and GSM3890631) human endometrium were obtained from GEO accession GSE132711 (SuperSeries GSE132713) (Chi et al, 2020). ChIPseq coverage data of proliferative and secretory normal endometrium were downloaded from GEO accession GSE132712 (SuperSeries GSE132713) (Chi et al, 2020). Human endometrial cancer RNAseq samples (n=575) were downloaded from The Cancer Genome Atlas (TCGA), project TCGA-UCEC. Additional normal and endometrial cancer samples (n=109) were accessed through CPTAC program in the National Cancer Institute using cptac platform installed with python (Dou et al, 2020).
-
Endometrial transcriptome and PGR cistrome in cycling fertile womenNCBI Gene Expression Omnibus, GSE132713.
-
Hormone induced repression of genes requires BRG1-mediated H1.2 deposition at target promotersNCBI Gene Expression Omnibus, GSE83785.
-
Nucleosome driven transcription factor binding and gene regulationNCBI Gene Expression Omnibus, GSE41466.
Article and author information
Author details
Funding
Consejo Nacional de Investigaciones Científicas y Técnicas (PIP 2015-682)
- Patricia Saragüeta
Fondo para la Investigación Científica y Tecnológica (PICT 2015-3426)
- Patricia Saragüeta
H2020 European Research Council (FP7/2007-2013 grant agreement 609989)
- Miguel Beato
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2022, La Greca et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,919
- views
-
- 290
- downloads
-
- 18
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Medicine
A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.
-
- Cancer Biology
- Chromosomes and Gene Expression
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.